Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Molecular Biology » MB-CD Markers » CD115, Recombinant, Human, Fc Chimera (BSA Free) (c-fms, Fms, CSF-1R, M-CSFR)

CD115, Recombinant, Human, Fc Chimera (BSA Free) (c-fms, Fms, CSF-1R, M-CSFR)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

CD115 is also known as c-fms, marcophage colony stimulating factor receptor, or CSF-1R. It exists in immature (gp130 c-fms) and mature (gp150 c-fms) forms. CSF-1R exhibits an intrinsic tyrosine-specific protein kinase activity. It is expressed on the cells of the mononuclear phagocyte lineage. CSF-1R is an integral transmembrane glycoprotein consisting of a 512 amino acid extracellular domain that includes the CSF-1 binding site, a single 25 amino acid membrane-spanning segment, and a 435 amino acid cytoplasmic portion that includes the tyrosine kinase domain.
Catalog #C2447-52E1
A DNA sequence encoding the extracellular domain of human M-CSF R (c-fms) (aa residue 1-512) (Coussens, L. et al., 1986, Nature 320277-280) was fused to the carboxy-terminal 6X histidine tagged Fc region of human IgG1 via a ploypeptide linker. The chimeric protein was expressed in a mouse myeloma cell line, NSO. Recombinant human M-CSF R/Fc chimera is a disulfide-linked homodimer. Each monomeric subunit, generated after the removal of a 19 residue signal peptide, contains 737 amino acid residues with a calculated molecular mass of 81kD. As a result of glycosylation, the monomeric subunits migrate as an approximately 150kD protein in SDS-PAGE under reducing conditions.
Human Macrophage Colony Stimulating Factor R/Fc Chimera M-CSF receptor, the product of the c-fms proto-oncogene, is a member of the type III subfamily of receptor tyrosine kinases that also includes Flt-3, the receptor for SCF, and the a and b receptors for PDGF. These receptors are characterized by the presence of five immunoglobulin-like domains in their extracellular region and a split kinase domain in their intracellular region. M-CSF binding induces receptor homodimerization, resulting in transphosphorylation of specific cytoplasmic tyrosine residues and signal transduction. The c-fms proto-oncogene has been mapped to chromosome 5 at band 5q33.3, in close proximity to the gene for the PDGF b receptor. M-CSF receptor is expressed primarily on cells of the monocyte/macrophage lineage and in various tissues of the developing placenta Human M-CSF receptor cDNA encodes a 972 amino acid residue type I membrane protein with a 23 aa residue putative signal peptide, a 489 aa residue extracellular region containing the ligand-binding domain, a 25 aa residue transmembrane domain and a 435 aa residue cytoplasmic domain. Activators of protein kinase C has been shown to induce the proteolytic cleavage of M-CSF receptor from the cell surface, resulting in the release of the functional ligand-binding extracellular domain. Recombinant soluble M-CSF R/Fc chimera binds M-CSF with high affinity and is a potent M-CSF antagonist (Sherr, C.J. 1990, Blood 751-12;
Hamilton, J.A., 1997, J. Leukoc. Biol. 62:145-155).
Source ¨ Human M-CSF R (Met 1-Glu 512) DIEGRMD Human IgG1 (Pro 100-Lys 330) HHHHHHN C
Endotoxin 0.1ng/mg of the cytokine as determined by the LAL method.
Activity Measured by its ability to inhibit the M-CSF induced proliferation of M-NFS-60 cells (Halenbeck, R. et al., 1989, Biotechnology 7:710). The ED50 for this effect is typically 0.004-0.012mg/ml in the presence of 1ng/ml of rhM-CSF.
Storage Lyophilized samples are stable for greater than six months at -20°C to -70°C. Upon reconstitution, this cytokine can be stored under sterile conditions at 2-4°C for one month
or at -20 to -70°C for three months without detectable loss of activity. Avoid repeated freeze-thaw cycles.
Purity97%, as determined by SDS-PAGE and visualized by silver stain.
ConcentrationAs reported
FormSupplied as a lyophilized powder from a 0.2um sterile-filtered solution in PBS. It is recommended that sterile PBS containing at least 0.1% HSA or BSA be added to the vial to prepare a stock solution of no less than 50mg/ml. Also available with BSA. See C2447-52E.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links